SCIENTISTS IDENTIFY KEY COMPONENT IN LETHAL LUNG CANCER COMPLICATION
COLUMBUS, Ohio – A protein previously thought not to exist in adult human lungs not only is present in normal and cancerous lung tissue, scientists have found, but it also has a major role in the development of a lethal complication of some lung cancers.
As these tumors grow, the receptor releases a hormone that sets off a biological cycle that leads to the erosion of bone throughout the body. When the bone breaks down, calcium is released. The excess calcium that can’t be filtered by kidneys cycles back to the receptors, which release more of the damaging hormone. That same hormone promotes the growth and spread of cancer.
The result is a syndrome called hypercalcemia, a debilitating disorder that signals lung cancer patients will survive only about three more months and eventually leads to acute multi-organ system failure.
Knowing the receptor’s role in squamous-cell lung cancers will help guide future research on new treatment options for both the cancer and hypercalcemia, said Gwendolen Lorch, assistant professor of veterinary clinical sciences at Ohio State University and lead author of the study.
“The calcium-sensing receptor clearly has a huge role in hypercalcemia. Though it’s too soon to say it could be a target for treatment, we won’t ever be able to find the right target if we don’t know how hypercalcemia develops in the first place,” Lorch said.
The researchers also found that lung cancer patients who have a specific type of inherited genetic mutation are at risk of developing hypercalcemia earlier than others. This finding is likely to have clinical implications in the future, as sequencing of the human genome becomes more affordable and available as part of standard medical care, Lorch said.
Before this study, previous research had established that the calcium-sensing receptor is important to lung development because mice lacking the receptor showed stunted lung growth. But its presence had never been documented in adult human lungs.
Researchers also knew that hypercalcemia was associated with unregulated release of a specific hormone, and that it developed in patients with cancers based in the epithelia, or tissue that makes up the lining of organs, blood vessels and body cavities. Squamous-cell carcinoma of the lung is one of these types of cancers.
Despite all that was known, however, the connection between the receptor and hypercalcemia had never been established in lung cancer. Studies suggest that anywhere from a fourth to two-thirds of lung cancer patients will develop the deadly syndrome.
Hypercalcemia symptoms include nausea and vomiting, loss of appetite, heart arrhythmia, high blood pressure and acute kidney failure. Most patients suffer dementia, become irritable and have sleep problems, and eventually have seizures, slip into a coma and die.
Some of the few treatment options available include two types of drugs that inhibit the bone loss. Fluid therapy also helps wash away the calcium. But Lorch said drugs that target the culprit hormone itself - known as PTHrP, or parathyroid hormone-related protein – are not available for human use.
“What we really need is something that works at the level of the tumor cell,” Lorch said. “We don’t have anything that can reduce the tumor burden and therefore reduce the production of PTHrP.”
In the study, Lorch and colleagues obtained squamous-cell lung cancer cell lines from three human patients. The researchers first showed with genetic data that all of these cells had produced proteins that indicated that the cells contained calcium-sensing receptors – a new finding in itself.
They then tested the cell lines to see how much calcium it would take for the receptors on those cells to produce the maximum amount of the PTHrP hormone. All three lines produced the highest hormone levels when the calcium concentration reached the equivalent of 12 milligrams per deciliter of calcium in blood in humans – the level at which hypercalcemia is diagnosed. Normal values range from 8.5 to 10.2 milligrams per deciliter.
“This told us that when people are hypercalcemic, they are producing the maximum level of PTHrP,” Lorch said.
An experiment in mice confirmed the calcium-sensing receptor’s role. Mice were injected with either regular tumor cells or cells from which the calcium-sensing receptor had been stripped away. Mice that received cells without the receptor developed hypercalcemia in 49 days, compared to 29 days for mice that received typical tumor cells, which do have the receptor.
“That’s a very big difference in time in mice,” Lorch said. “This suggests that the calcium-sensing receptor was necessary for the rapid development of hypercalcemia.”
The receptors on those cells also behaved as expected in additional cell line experiments exploring their behavior after the PTHrP hormone was released. All three lines led to the release of what is known as intercellular calcium, but at different levels and rates. One line in particular stood out. This line, called HARA, had previously produced the most PTHrP when stimulated with calcium, and then released much more excess calcium than the other two cell lines.
These findings in the tissue studies led the scientists to sequence the calcium-sensing receptors in the three cell lines to look for genetic variants. The HARA line contained a mutation known as a single nucleotide polymorphism, or SNP (pronounced snip), that influenced how much of the PTHrP protein the receptors produced and how much calcium it took to stimulate that action.
What this means is that lung cancer patients who have two copies of this mutation – one from each parent – are more likely to develop hypercalcemia even before their blood work shows elevated levels of calcium.
“The significance of this is if you have two copies of the mutation, it would be ideal for a clinician to know that you have this mutation and start pre-emptive fluid therapy or other preventive treatment. Even in the normal calcium range, this mutation is going to set a person up for hypercalcemia much earlier than other patients,” Lorch said.
This work was supported by grants from the National Institutes of Health.
Co-authors include Serge Viatchenko-Karpinski, Hsiang-Ting Ho and Sandor Györke of the Davis Heart and Lung Research Institute; Wessel Dirksen and Thomas Rosol of the Department of Veterinary Biosciences; and Ramiro Toribio of the Department of Veterinary Clinical Sciences, all at Ohio State; and John Foley of Indiana University.
Contact: Gwendolen Lorch, (614) 292-9698; email@example.com
Written by Emily Caldwell, (614) 292-8310; firstname.lastname@example.org